Electrochemiluminescence immunoassay method
An electrochemiluminescence immunoassay method is disclosed and uses a full reaction of a Ru(bpy) marked protein-primary antibody, a biotinylated protein-secondary antibody to be tested, and a sample to be tested; addition of a Streptavidin-coated magnetic particle to form a complex comprising an antigen, an antibody, and a magnetic particle; adsorption to an electrode surface by the magnetic particle; addition of a dibutyl ethanolamine solution; and testing by an electrochemical method. Also disclosed is a corresponding electrochemiluminescence immunoassay detection kit.
1. An electrochemiluminescence (ECL) immunoassay method comprising:
step 1 of (i) reacting a ruthenium pyridine-labeled primary antibody that binds to a protein of interest with a biotinylated secondary antibody that binds to the protein of interest and with a sample, or (ii) reacting a ruthenium pyridine-labeled antibody that binds to a protein of interest with a biotinylated protein of interest and with a sample;
step 2 of adding magnetic particles coated with streptavidin to the mixture of step (a) to form a complex comprising the protein of interest, the antibody and the magnetic particle which is then transferred into a flow cell, wherein the complex is adsorbed onto the surface of an electrode through the magnetic particle;
step 3 of adding a dibutyl ethanolamine solution and applying voltage to the mixture of step (b) to initiate an ECL reaction, and collecting scanned optical signals with an optical detector; and
step 4 of providing solutions having a gradient of concentrations of the protein of interest, performing steps 1-3 on these solutions, and plotting a dose-response curve according to the logarithm of changes in the value of luminescence intensity and the logarithm of concentration, thereby obtaining the concentration of the protein of interest in the sample;
wherein the structure of ruthenium pyridine is
wherein the magnetic particle is a polystyrene particle having a diameter of 2.8 μm;
wherein step 1 is performed under a liquid phase condition at 37° C. for 8 min, and step 2 is performed under a near liquid phase condition at 37° C. for 8 min,
wherein the protein of interest is Thyroid-stimulating hormone (“TSH”), free triiodothyronine (“FT3”), or carcinoembryonic antigen (“CEA”).
2. The electrochemiluminescence immunoassay method according to claim 1 , wherein the sample is serum, urine, or tissue fluid.